Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 versus LIPO HEPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 versus LIPO HEPIN.
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% vs LIPO-HEPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing clot formation and extension.
LIPO-HEPIN (unfractionated heparin) binds to antithrombin III, accelerating the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby inhibiting coagulation.
IV continuous infusion: initial bolus 80 units/kg, then maintenance 18 units/kg/hour; titrate to aPTT 1.5-2.5 times control. The solution HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% is typically used for continuous infusion; dose should be adjusted based on patient weight and aPTT.
Initial IV bolus 80 units/kg, then continuous IV infusion 18 units/kg/hr; or subcutaneous 5000 units every 8-12 hours. Dose adjusted based on aPTT.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (mean 1.6 h) at therapeutic doses, but is dose-dependent: 30-60 min after 25 U/kg, 1-2 h after 100-200 U/kg, and 2.5-5 h after 400-800 U/kg. Half-life is prolonged in hepatic or renal impairment.
1-2 hours (therapeutic doses); dose-dependent: 30-60 min at low doses, up to 4-6 hours at high doses. Heparin is eliminated by a saturable zero-order process, leading to nonlinear pharmacokinetics. Clinical context: prolonged half-life in renal impairment or hepatic disease.
Heparin is eliminated primarily via the reticuloendothelial system and renal excretion. Approximately 50% is excreted unchanged in urine via saturable zero-order kinetics, with the remainder metabolized to uroheparin and other inactive metabolites. Biliary/fecal excretion is negligible (<5%).
Renal: 30-60% as unchanged drug; minor biliary/fecal (<10%). Clearance predominantly via hepatic metabolism (desulfation) and reticuloendothelial system uptake.
Category A/B
Category C
Anticoagulant
Anticoagulant